Omeros Q3 net revenue rises 26% on YARTEMLEA sales
Overview
US biotechnology firm's Q3 net revenue rose 26% sequentially on YARTEMLEA sales growth
Company posted GAAP net loss due to non-cash loss on convertible notes; reported non-GAAP adjusted net income
Omeros repurchased $30.5 mln of 2029 Notes, reducing interest obligations and potential share dilution
Outlook
Company says YARTEMLEA revenues continue to grow into the fourth quarter
Omeros expects to initiate clinical studies for YARTEMLEA in ARDS and TA-TMA prevention in late 2026 or early 2027
Company anticipates near-term milestone payments from Novo related to zaltenibart development
Result Drivers
YARTEMLEA SALES GROWTH - Co said higher sales were driven by expanded customer base and increased outpatient use of YARTEMLEA
340B PARTICIPATION - Co said higher purchases by 340B entities contributed to increased gross-to-net adjustment and supported outpatient utilization goals
FIELD EDUCATION AND REIMBURSEMENT - Co said investments in field education and new Medicare reimbursement advantages are supporting continued sales momentum
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.79 | ||
Q3 Net Loss | $57.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Omeros Corporation is $33.00, about 88.7% above its November 13 closing price of $17.49
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 397 three months ago
Reuters Recommended Reads
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances
Nov 16 - AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)